Published in Gene Therapy Weekly, September 25th, 1995
The collaboration will combine Myriad's strengths in gene discovery and gene characterization with Bayer's drug discovery, development and marketing expertise.
Myriad received a $10 million equity investment from Bayer and, under the terms of the agreement, will receive $25 million in research payments over the five year period. In addition, Bayer will provide Myriad with up to $36 million in milestone payments...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Gene Therapy Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.